Anagrelide: 20 years later

Expert Review of Anticancer Therapy

Volumn 9, Issue 1, 2009, Pages 37-50

  Emadi, Ashkan ^a   Spivak, Jerry L ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anagrelide; Essential thrombocytosis; Myeloproliferative disorder

Indexed keywords

2 AMINO 5,6 DICHLORO 3,4 DIHYDROQUINAZOLINE; ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; ANTITHROMBOCYTIC AGENT; BUSULFAN; CLOPIDOGREL; DIPYRIDAMOLE; HYDROXYUREA; JANUS KINASE 2; PARACETAMOL; PEGINTERFERON ALPHA; PHOSPHODIESTERASE III INHIBITOR; PIPOBROMAN; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; QUINAZOLINE DERIVATIVE;

ABDOMINAL PAIN; ACUTE LEUKEMIA; ALLERGIC PNEUMONITIS; ALOPECIA; ANGINA PECTORIS; AREA UNDER THE CURVE; ARTERY THROMBOSIS; ASTHENIA; BLEEDING; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG WITHDRAWAL; EDEMA; ERYTHROMELALGIA; ESSENTIAL THROMBOCYTOSIS; EXTREME THROMBOCYTOSIS; FLU LIKE SYNDROME; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HEART ARRHYTHMIA; HEART FAILURE; HEART PALPITATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INOTROPISM; LEG ULCER; LIVER VEIN THROMBOSIS; LONG TERM CARE; LOW DRUG DOSE; LUNG EMBOLISM; LUNG FIBROSIS; LUNG INFILTRATE; MICROANGIOPATHY; MOUTH ULCER; MYALGIA; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PERICARDIAL EFFUSION; PLEURA EFFUSION; POLYCYTHEMIA VERA; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOPOIESIS; THROMBOCYTOSIS; THROMBOEMBOLISM; THROMBOPHLEBITIS; THROMBOSIS PREVENTION; TRANSIENT ISCHEMIC ATTACK; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; WEAKNESS; WEIGHT REDUCTION;

HUMANS; MYELOPROLIFERATIVE DISORDERS; PLATELET AGGREGATION INHIBITORS; QUINAZOLINES; THROMBOCYTOSIS;

EID: 61449558789     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.9.1.37     Document Type: Review

References (130)

1. Budde U, van Genderen PJ. Acquired von Willebrand disease in patients with high platelet counts. Semin. Thromb. Hemost. 23(5), 425-431 (1997).
2. Michiels JJ, Berneman Z, Schroyens W, Finazzi G, Budde U, van Vliet HH. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin. Thromb. Hemost. 32(6), 589-604 (2006).
3. Michiels JJ, Abels J, Steketee J, van Vliet HH, Vuzevski VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann. Intern. Med. 102(4), 466-471 (1985).
4. Michiels JJ, Koudstaal PJ, Mulder AH, van Vliet HH. Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology, 43(6), 1107-1110 (1993).
5. Jabaily J, Iland HJ, Laszlo J et al. Neurologic manifestations of essential thrombocythemia. Ann. Intern. Med. 99(4), 513-518 (1983).
6. Michiels JJ, van Genderen PJ, Jansen PH, Koudstaal PJ. Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders. Leuk. Lymphoma 22(Suppl. 1), 65-70 (1996).
7. Fleming JS, Buyniski JP. A potent new inhibitor of platelet aggregation and experimental thrombosis, anagrelide (BL-4162A). Thromb. Res. 15(3-4), 373-388 (1979).
8. Baryla UM, Fleming JS, Stanton HC. The anesthetized ferret, an in vivo model for evaluating inotropic activity: effects of milrinone and anagrelide. J. Pharmacol. Methods 20(4), 299-306 (1988).
9. Wang G, Franklin R, Hong Y, Erusalimsky JD. Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures. Br. J. Pharmacol. 146(3), 324-332 (2005).
10. Gaver RC, Deeb G, Pittman KA, Smyth RD. Disposition of anagrelide, an inhibitor of platelet aggregation. Clin. Pharmacol. Ther. 29(3), 381-386 (1981).
11. Oertel MD. Anagrelide, a selective thrombocytopenic agent. Am. J. Health Syst. Pharm. 55(19), 1979-1986 (1998).
12. Wagstaff AJ, Keating GM. Anagrelide: a review of its use in the management of essential thrombocythaemia. Drugs 66(1), 111-131 (2006).
13. Tomer A. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood 99(5), 1602-1609 (2002).
14. Mazur EM, Rosmarin AG, Sohl PA, Newton JL, Narendran A. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 79(8), 1931-1937 (1992).
15. Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA Jr. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications. Semin. Thromb. Hemost. 23(4), 379-383 (1997).
16. Hong Y, Wang G, Del Arroyo AG, Hernandez J, Skene C, Erusalimsky JD. Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage. Leukemia 20(6), 1117-1122 (2006).
17. Lane WJ, Hattori K, Dias S et al. Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation. Exp. Hematol. 29(12), 1417-1424 (2001).
18. Erusalimsky JD, Hong Y, Franklin R. Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5,6-dichloro-3,4-dihydroquinazoline (RL603)? Exp. Hematol. 30(7), 625-626; author reply: 626-627 (2002).
19. McCarty JM, Melone PD, Simanis JP, Kanamori D, Dessypris EN, Warshamana-Greene GS. A preliminary investigation into the action of anagrelide: thrombopoietin-c-Mpl receptor interactions. Exp. Hematol. 34(1), 87-96 (2006).
20. Birgegard G, Bjorkholm M, Kutti J et al. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica 89(5), 520-527 (2004).
21. Solberg LA Jr, Tefferi A, Oles KJ et al. The effects of anagrelide on human megakaryocytopoiesis. Br. J. Haematol. 99(1), 174-180 (1997).
22. Tomer A, Harker LA. Measurements of in vivo megakaryocytopoiesis: studies in nonhuman primates and patients. Stem Cells 14(Suppl. 1), 18-30 (1996).
23. Thiele J, Kvasnicka HM, Ollig S, Schmitt-Graff A. Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative immunohistochemical and morphometric study with hydroxyurea. Histol. Histopathol. 20(4), 1071-1076 (2005).
24. Yoon SY, Li CY, Mesa RA, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br. J. Haematol. 106(3), 682-688 (1999).
25. Cacciola RR, Francesco ED, Giustolisi R, Cacciola E. Effects of anagrelide on platelet factor 4 and vascular endothelial growth factor levels in patients with essential thrombocythemia. Br. J. Haematol. 126(6), 885-886 (2004).
26. Cacciola RR, Cipolla A, Di Francesco E, Giustolisi R, Cacciola E. Treatment of symptomatic patients with essential thrombocythemia: effectiveness of anagrelide. Am. J. Hematol. 80(1), 81-83 (2005).
27. Lev PR, Salim JP, Kornblihtt LI et al. PDGF-A, PDGF-B, TGFΒ, and bFGF mRNA levels in patients with essential thrombocythemia treated with anagrelide. Am. J. Hematol. 78(2), 155-157 (2005).
28. Thiele J, Kvasnicka HM, Fuchs N, Brunnbauer K, Volkwein N, Schmitt-Graeff A. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies. Haematologica 88(10), 1130-1138 (2003).
29. Silverstein MN, Petitt RM, Solberg LA Jr, Fleming JS, Knight RC, Schacter LP. Anagrelide: a new drug for treating thrombocytosis. N. Engl. J. Med. 318(20), 1292-1294 (1988).
30. Mazzucconi MG, De Sanctis V, Chistolini A, Dragoni F, Mandelli F. Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results. Haematologica 77(4), 315-317 (1992).
31. Balduini CL, Bertolino G, Noris P, Ascari E. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Haematologica 77(1), 40-43 (1992).
32. Petrides PE, Beykirch MK, Trapp OM. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. Eur. J. Haematol. 61(2), 71-76 (1998).
33. Trapp OM, Beykirch MK, Petrides PE. Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count. Blood Cells Mol. Dis. 24(1), 9-13 (1998).
34. Mills AK, Taylor KM, Wright SJ et al. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia. Aust. NZ J. Med. 29(1), 29-35 (1999).
35. Laguna MS, Kornblihtt LI, Marta RF, Michiels JJ, Molinas FC. Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Clin. Appl. Thromb. Hemost. 6(3), 157-161 (2000).
36. Knutsen H, Hysing J. [Anagrelide in primary thrombocythemia]. Tidsskr. Nor. Laegeforen. 121(12), 1478-1482 (2001).
37. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 97(4), 863-866 (2001).
38. Kornblihtt LI, Vassallu PS, Heller P, Molinas FC. [Treatment of essential thrombocythemia with anagrelide: a ten-year experience]. Medicina (B. Aires) 62(3), 231-236 (2002).
39. Mazzucconi MG, Redi R, Bernasconi S et al. A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica 89(11), 1306-1313 (2004).
40. Steurer M, Gastl G, Jedrzejczak WW et al. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 101(10), 2239-2246 (2004).
41. Penninga E, Jensen BA, Hansen PB et al. Anagrelide treatment in 52 patients with chronic myeloproliferative diseases. Clin. Lab. Haematol. 26(5), 335-340 (2004).
42. Silver RT. Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia. Leukemia 19(1), 39-43 (2005).
43. Penka M, Schwarz J, Pavlik T et al. [Essential thrombocytemia and other myeloproliferations with thrombocytemia in the data of the register of patients treated with Thromboreductin till the end of 2006]. Vnitr Lek. 53(6), 653-661 (2007).
44. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am. J. Med. 92(1), 69-76 (1992).
45. Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin. Hematol. 34(1), 51-54 (1997).
46. Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A. Anagrelide: analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk. Res. 29(5), 481-491 (2005).
47. Lackner H, Urban C, Benesch M et al. Long-term use of anagrelide in the treatment of children with essential thrombocythemia. Eur. J. Haematol. 77(4), 358-359 (2006).
48. Harrison CN, Campbell PJ, Buck G et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N. Engl. J. Med. 353(1), 33-45 (2005).
49. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin. Hematol. 34(1), 29-39 (1997).
50. Cassinat B, Laguillier C, Gardin C et al. Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? Leukemia 22(2), 452-453 (2008).
51. Carobbio A, Finazzi G, Guerini V et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109(6), 2310-2313 (2007).
52. Falanga A, Marchetti M, Evangelista V et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 96(13), 4261-4266 (2000).
53. Cokic VP, Beleslin-Cokic BB, Tomic M, Stojilkovic SS, Noguchi CT, Schechter AN. Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. Blood 108(1), 184-191 (2006).
54. Cokic VP, Andric SA, Stojilkovic SS, Noguchi CT, Schechter AN. Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells. Blood 111(3), 1117-1123 (2008).
55. Gambero S, Canalli AA, Traina F et al. Therapy with hydroxyurea is associated with reduced adhesion molecule gene and protein expression in sickle red cells with a concomitant reduction in adhesive properties. Eur. J. Haematol. 78(2), 144-151 (2007).
56. Canalli AA, Franco-Penteado CF, Saad ST, Conran N, Costa FF. Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation. Haematologica 93(4), 605-609 (2008).
57. Petrides PE. Anagrelide: what was new in 2004 and 2005? Semin. Thromb. Hemost. 32(4 Pt 2), 399-408 (2006).
58. Campbell PJ, Scott LM, Buck G et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366(9501), 1945-1953 (2005).
59. Raghavan M, Mazer MA, Brink DJ. Severe hypersensitivity pneumonitis associated with anagrelide. Ann. Pharmacother. 37(9), 1228-1231 (2003).
60. Rodwell GE, Troxell ML, Lafayette RA. Renal tubular injury associated with anagrelide use. Nephrol. Dial. Transplant. 20(5), 988-990 (2005).
61. Wong RS, Lam LW, Cheng G. Successful rechallenge with anagrelide in a patient with anagrelide-associated cardiomyopathy. Ann. Hematol. DOI: 10.1007/s00277-008-0451-6 (2008)
62. Hultdin M, Sundstrom G, Wahlin A et al. Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Med. Oncol. 24(1), 63-70 (2007).
63. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100(7), 2292-2302 (2002).
64. Kaushansky K. Historical review: megakaryopoiesis and thrombopoiesis. Blood 111(3), 981-986 (2008).
65. Stenberg PE, Levin J. Mechanisms of platelet production. Blood Cells 15(1), 23-47 (1989).
66. Patel SR, Hartwig JH, Italiano JE Jr. The biogenesis of platelets from megakaryocyte proplatelets. J. Clin. Invest. 115(12), 3348-3354 (2005).
67. Ravid K, Lu J, Zimmet JM, Jones MR. Roads to polyploidy: the megakaryocyte example. J. Cell. Physiol. 190(1), 7-20 (2002).
68. Odell TT Jr, Jackson CW, Friday TJ. Megakaryocytopoiesis in rats with special reference to polyploidy. Blood 35(6), 775-782 (1970).
69. Patel SR, Richardson JL, Schulze H et al. Differential roles of microtubule assembly and sliding in proplatelet formation by megakaryocytes. Blood 106(13), 4076-4085 (2005).
70. Richardson JL, Shivdasani RA, Boers C, Hartwig JH, Italiano JE Jr. Mechanisms of organelle transport and capture along proplatelets during platelet production. Blood 106(13), 4066-4075 (2005).
71. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J. Clin. Invest. 115(12), 3339-3347 (2005).
72. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 85(10), 2720-2730 (1995).
73. Wolber EM, Fandrey J, Frackowski U, Jelkmann W. Hepatic thrombopoietin mRNA is increased in acute inflammation. Thromb. Haemost. 86(6), 1421-1424 (2001).
74. Kaser A, Brandacher G, Steurer W et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood 98(9), 2720-2725 (2001).
75. Syed NN, Usman M, Khurshid M. Thrombocytosis: age dependent aetiology and analysis of platelet indices for differential diagnosis. Indian J. Pathol. Microbiol. 50(3), 628-633 (2007).
76. Aydogan T, Kanbay M, Alici O, Kosar A. Incidence and etiology of thrombocytosis in an adult Turkish population. Platelets 17(5), 328-331 (2006).
77. Griesshammer M, Bangerter M, Sauer T, Wennauer R, Bergmann L, Heimpel H. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J. Intern. Med. 245(3), 295-300 (1999).
78. Santhosh-Kumar CR, Yohannan MD, Higgy KE, al-Mashhadani SA. Thrombocytosis in adults: analysis of 777 patients. J. Intern. Med. 229(6), 493-495 (1991).
79. Tefferi A, Murphy S. Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management. Blood Rev. 15(3), 121-131 (2001).
80. Buss DH, Stuart JJ, Lipscomb GE. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases. Am. J. Hematol. 20(4), 365-372 (1985).
81. Bellucci S, Janvier M, Tobelem G et al. Essential thrombocythemias. Clinical evolutionary and biological data. Cancer 58(11), 2440-2447 (1986).
82. Wehmeier A, Daum I, Jamin H, Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann. Hematol. 63(2), 101-106 (1991).
83. 9/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br. J. Haematol. 100(1), 15-23 (1998).
84. Besses C, Cervantes F, Pereira A et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 13(2), 150-154 (1999).
85. Landolfi R, Rocca B, Patrono C. Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. Crit. Rev. Oncol. Hematol. 20(3), 203-222 (1995).
86. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br. J. Haematol. 128(3), 275-290 (2005).
87. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J. Clin. Oncol. 8(3), 556-562 (1990).
88. Tefferi A, Fonseca R, Pereira DL, Hoagland HC. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin. Proc. 76(1), 22-28 (2001).
89. Wiwanitkit V. Extreme thrombocytosis: what are the etiologies? Clin. Appl. Thromb. Hemost. 12(1), 85-87 (2006).
90. Buss DH, Cashell AW, O'Connor ML, Richards F 2nd, Case LD. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am. J. Med. 96(3), 247-253 (1994).
91. Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia. Semin. Thromb. Hemost. 32(3), 171-173 (2006).
92. Green AR, Vassiliou GS, Curtin N, Campbell PJ. Management of the myeloproliferative disorders: distinguishing data from dogma. Hematol. J. 5(Suppl. 3), S126-S132 (2004).
93. Ruggeri M, Tosetto A, Frezzato M, Rodeghiero F. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann. Intern. Med. 139(6), 470-475 (2003).
94. Campbell PJ, Green AR. The myeloproliferative disorders. N. Engl. J. Med. 355(23), 2452-2466 (2006).
95. Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 67(10), 2658-2663 (1991).
96. Passamonti F, Rumi E, Pungolino E et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am. J. Med. 117(10), 755-761 (2004).
97. Moliterno AR, Williams DM, Rogers O, Spivak JL. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 108(12), 3913-3915 (2006).
98. Wilkins BS, Erber WN, Bareford D et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 111(1), 60-70 (2008).
99. Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis and primary myelofibrosis: an alternative proposal. Blood 112(2), 231-239 (2008).
100. Schmitt-Graeff AH, Teo SS, Olschewski M et al. JAK2 V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 93(1), 34-40 (2008).
101. Spivak JL. Phenotype and genotype in the myeloproliferative disorders. Eur. J. Haematol. 79(Suppl. 68), 9-12 (2007).
102. Percy MJ, Jones FG, Green AR, Reilly JT, McMullin MF. The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis. Haematologica 91(3), 413-414 (2006).
103. Jantunen R, Juvonen E, Ikkala E, Oksanen K, Anttila P, Ruutu T. Development of erythrocytosis in the course of essential thrombocythemia. Ann. Hematol. 78(5), 219-222 (1999).
104. Landolfi R, Marchioli R, Kutti J et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N. Engl. J. Med. 350(2), 114-124 (2004).
105. Finazzi G, Barbui T. How I treat patients with polycythemia vera. Blood 109(12), 5104-5111 (2007).
106. Barbui T, Barosi G, Grossi A et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 89(2), 215-232 (2004).
107. Cortelazzo S, Finazzi G, Ruggeri M et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N. Engl. J. Med. 332(17), 1132-1136 (1995).
108. Ruggeri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T. No treatment for low-risk thrombocythaemia: results from a prospective study. Br. J. Haematol. 103(3), 772-777 (1998).
109. Vannucchi AM, Antonioli E, Guglielmelli P et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 110(3), 840-846 2007).
110. Wolanskyj AP, Lasho TL, Schwager SM et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br. J. Haematol. 131(2), 208-213 (2005).
111. De Stefano V, Za T, Rossi E et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 93(3), 372-380 2008).
112. Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol. 85(3), 124-127 (1991).
113. Finazzi G, Barbui T. Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev. 19(5), 243-252 (2005).
114. Finazzi G, Barbui T. Treatment of essential thrombocythemia with special emphasis on leukemogenic risk. Ann. Hematol. 78(9), 389-392 (1999).
115. Spivak JL, Barosi G, Tognoni G et al. Chronic myeloproliferative disorders. Hematology 200-224 (2003).
116. Best PJ, Petitt RM. Multiple skin cancers associated with hydroxyurea therapy. Mayo Clin. Proc. 73(10), 961-963 (1998).
117. De Benedittis M, Petruzzi M, Giardina C, Lo Muzio L, Favia G, Serpico R. Oral squamous cell carcinoma during long-term treatment with hydroxyurea. Clin. Exp. Dermatol. 29(6), 605-607 (2004).
118. Adams M, Warr JR. The mutagenic activity of hydroxyurea in Chlamydomonas reinhardi. Mutat. Res. 41(2-3), 217-224 (1976).
119. Ziegler-Skylakakis K, Schwarz LR, Andrae U. Microsome- and hepatocyte-mediated mutagenicity of hydroxyurea and related aliphatic hydroxamic acids in V79 Chinese hamster cells. Mutat. Res. 152(2-3), 225-231 (1985).
120. de Lima PD, Cardoso PC, Khayat AS, Bahia Mde O, Burbano RR. Evaluation of the mutagenic activity of hydroxyurea on the G1-S-G2 phases of the cell cycle: an in vitro study. Genet. Mol. Res. 2(3), 328-333 (2003).
121. Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am. J. Hematol. 74(1), 26-31 (2003).
122. Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 90(9), 3370-3377 (1997).
123. Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin. Thromb. Hemost. 32(4 Pt 2), 417-421 (2006).
124. Lengfelder E, Griesshammer M, Hehlmann R. Interferon-α in the treatment of essential thrombocythemia. Leuk. Lymphoma 22(Suppl. 1), 135-142 (1996).
125. Griesshammer M, Bergmann L, Pearson T. Fertility, pregnancy and the management of myeloproliferative disorders. Baillieres Clin. Haematol. 11(4), 859-874 (1998).
126. 2a. Blood 108(6), 2037-2040 (2006).
127. Lengfelder E, Berger U, Hehlmann R. Interferon a in the treatment of polycythemia vera. Ann. Hematol. 79(3), 103-109 (2000).
128. Bartholomew JR, Salgia R, Bell WR. Control of bleeding in patients with immune and nonimmune thrombocytopenia with aminocaproic acid. Arch. Intern. Med. 149(9), 1959-1961 (1989).
129. Ogston D. Current status of antifibrinolytic drugs. Blood Rev. 3(1), 1-4 (1989).
130. Ziakas PD. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain. Haematologica 93(9), 1412-1414 (2008).